Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
Compare

SMFL vs. ADTX, CMRA, EVLO, EFTR, and STAB

Should you buy Smart for Life stock or one of its competitors? Smart for Life's main competitors and comparable companies include Aditxt (ADTX), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), eFFECTOR Therapeutics (EFTR), and Statera Biopharma (STAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Smart for Life compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

In the previous week, Aditxt had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for Smart for Life. Aditxt's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Aditxt Neutral
Smart for Life Neutral

Aditxt has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.74, meaning that its stock price is 1,674% more volatile than the broader market.

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Smart for Life N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Smart for Life
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Smart for Life has higher revenue and earnings than Aditxt. Smart for Life is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.18-$41.71M-$100.79 thousandN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Aditxt on 9 of the 13 factors compared between the two stocks.

How does Smart for Life compare to Comera Life Sciences?

Smart for Life (NASDAQ:SMFL) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Comera Life Sciences Neutral

Smart for Life has a beta of 17.74, meaning that its share price is 1,674% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has lower revenue, but higher earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

Smart for Life beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Evelo Biosciences?

Smart for Life (NASDAQ:SMFL) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Smart for Life has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Evelo Biosciences Neutral

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Smart for Life has a beta of 17.74, meaning that its stock price is 1,674% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Summary

Smart for Life beats Evelo Biosciences on 6 of the 7 factors compared between the two stocks.

How does Smart for Life compare to eFFECTOR Therapeutics?

Smart for Life (NASDAQ:SMFL) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
eFFECTOR Therapeutics Neutral

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$8.83N/A

Smart for Life has a beta of 17.74, meaning that its share price is 1,674% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Statera Biopharma?

Statera Biopharma (NASDAQ:STAB) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Smart for Life Neutral

Statera Biopharma has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, Smart for Life has a beta of 17.74, meaning that its share price is 1,674% more volatile than the broader market.

Statera Biopharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Smart for Life N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Smart for Life beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.34B$7.20B$13.28B
Dividend YieldN/A2.65%2.53%16.36%
P/E Ratio0.00797.65274.6326.11
Price / SalesN/A833.42586.3181.01
Price / CashN/A86.1776.8253.72
Price / BookN/A10.6410.936.31
Net Income-$22.68M$2.84B$3.50B$381.90M

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/AN/AN/A-97.3%$1K$11.11MN/A110
ADTX
Aditxt
0.0399 of 5 stars		$0.00
-8.8%		N/A-100.0%$3K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A66
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$1KN/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel